Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

New England Journal of Medicine

Volumn 366, Issue 7, 2012, Pages 601-609

  Agnelli, Giancarlo ^a   George, Daniel J ^b   Kakkar, Ajay K ^c   Fisher, William ^d   Lassen, Michael R ^e   Mismetti, Patrick ^f   Mouret, Patrick ^g   Chaudhari, Umesh ^h   Lawson, Francesca ^h   Turpie, Alexander G G ⁱ  

^a UNIVERSITY OF PERUGIA   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITÉ JEAN MONNET   (France)

^g Klinikum Frankfurt   (Germany)

^h SANOFI   (France)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEMULOPARIN;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84857129296     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1108898     Document Type: Article

References (42)

1. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-35.
2. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
3. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50. (Pubitemid 32104130)
4. Stein PD, Beemath A, Meyers FA, Kayali F, Skaf E, Olson RE. Pulmonary embolism as a cause of death in patients who died with cancer. Am J Med 2006;119:163-5. (Pubitemid 43151483)
5. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95. (Pubitemid 43054059)
6. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46. (Pubitemid 350100757)
7. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190-4. (Pubitemid 38140406)
8. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapyassociated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-9. (Pubitemid 41798294)
9. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8. (Pubitemid 351404927)
10. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4. (Pubitemid 46680709)
11. Levine M, Hirsh J, Gent M, et al. Double- blind randomised trial of a very-lowdose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9. (Pubitemid 24113632)
12. Haas SK, Kakkar AK, Kemkes-Mattes B, et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC Studies. J Thromb Haemost 2005;3:Suppl 1:OR059. abstract.
13. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecularweight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8:1959-65.
14. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo controlled, doubleblind study. Lancet Oncol 2009;10:943-9.
15. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505. (Pubitemid 350232226)
16. Mandalà M, Falanga A, Roila F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol 2010;21: Suppl 5:v274-v276.
17. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133: Suppl:381S-453S. (Pubitemid 351894916)
18. Viskov C, Just M, Laux V, Mourier P, Lorenz M. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecularweight heparin, AVE5026. J Thromb Haemost 2009;7:1143-51.
19. Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a doseranging study. J Thromb Haemost 2009; 7:566-72.
20. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975;31:103-15.
21. Freedman LS, White SJ. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976;32:691-4.
22. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
23. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: 496-509.
25. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986;73:751-4.
26. Lewis JH. "Hy's law," the "Rezulin rule," and other predictors of severe druginduced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221-9.
27. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61. [Erratum, Arch Intern Med 2008;168:1218.] (Pubitemid 39037944)
28. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-8. (Pubitemid 35303914)
29. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003;349:109-11. (Pubitemid 36818779)
30. Haddad TC, Greeno EW. Chemotherapy- induced thrombosis. Thromb Res 2006; 118:555-68.
31. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy- induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 2002;88:213-20. (Pubitemid 34873701)
32. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecanand bevacizumab-based therapy. J Clin Oncol 2005;23:2574-6. (Pubitemid 47053842)
33. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9. [Errata, J Natl Cancer Inst 2008;100:156, 685.] (Pubitemid 47299901)
34. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85.
35. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27: 4865-73.
36. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab- based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11:733-40.
37. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:1757-64.
38. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830-40.
39. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-8.
40. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood 2008;111:4902-7.
41. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-82.
42. Streiff MB, Bockenstedt PL, Cataland SR, et al. Venous thromboembolic disease. J Natl Compr Canc Netw 2011;9:714-77.